The role of endoglin in atherosclerosis

Atherosclerosis

Volumn 224, Issue 1, 2012, Pages 4-11

  Nachtigal, Petr ^a   Zemankova Vecerova, Lenka ^a   Rathouska, Jana ^a   Strasky, Zbynek ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Atherosclerosis; Cholesterol; Endoglin; Statins; TGF 1 signaling

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; COLLAGEN; ENDOGLIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; BLOOD VESSEL; BLOOD VESSEL WALL; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; ENDOTHELIUM CELL; EXPERIMENTAL ANIMAL; EXTRACORPOREAL CIRCULATION; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERTENSION; IN VITRO STUDY; MEMBRANE STABILIZATION; MESENCHYME CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

ANIMALS; ANTIGENS, CD; ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MICE; NITRIC OXIDE SYNTHASE TYPE III; PLAQUE, ATHEROSCLEROTIC; PROTEOGLYCANS; PYRROLES; RECEPTORS, CELL SURFACE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SWINE;

EID: 84865391736     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.03.001     Document Type: Review

References (76)

1. Assoian R.K., Komoriya A., Meyers C.A., et al. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem 1983, 258:7155-7160.
2. Singh N.N., Ramji D.P. The role of transforming growth factor-beta in atherosclerosis. Cytokine Growth Factor Rev 2006, 17:487-499.
3. Mallat Z., Gojova A., Marchiol-Fournigault C., et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2001, 89:930-934.
4. Nikol S., Isner J.M., Pickering J.G., et al. Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J Clin Invest 1992, 90:1582-1592.
5. Chen J.K., Hoshi H., McKeehan W.L. Transforming growth factor type beta specifically stimulates synthesis of proteoglycan in human adult arterial smooth muscle cells. Proc Natl Acad Sci U S A 1987, 84:5287-5291.
6. O'Brien K.D., Olin K.L., Alpers C.E., et al. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation 1998, 98:519-527.
7. Grainger D.J., Kemp P.R., Metcalfe J.C., et al. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med 1995, 1:74-79.
8. Albert M.A., Danielson E., Rifai N., Ridker P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001, 286:64-70.
9. Blanco F.J., Santibanez J.F., Guerrero-Esteo M., et al. Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol 2005, 204:574-584.
10. Feinberg M.W., Jain M.K. Role of transforming growth factor-beta1/Smads in regulating vascular inflammation and atherogenesis. Panminerva Med 2005, 47:169-186.
11. Lebrin F., Deckers M., Bertolino P., Ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc Res 2005, 65:599-608.
12. Llorca O., Trujillo A., Blanco F.J., Bernabeu C. Structural model of human endoglin, a transmembrane receptor responsible for hereditary hemorrhagic telangiectasia. J Mol Biol 2007, 365:694-705.
13. Perez-Gomez E., Del Castillo G., Juan Francisco S., et al. The role of the TGF-beta coreceptor endoglin in cancer. Sci World J 2010, 10:2367-2384.
14. De Vivo A., Baviera G., Giordano D., et al. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 2008, 87:837-842.
15. Lopez-Novoa J.M., Bernabeu C. The physiological role of endoglin in the cardiovascular system. Am J Physiol Heart Circ Physiol 2010, 299:H959-H974.
16. Blazquez-Medela A.M., Garcia-Ortiz L., Gomez-Marcos M.A., et al. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med 2010, 8:86.
17. Cheifetz S., Bellon T., Cales C., et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 1992, 267:19027-19030.
18. Bernabeu C., Conley B.A., Vary C.P. Novel biochemical pathways of endoglin in vascular cell physiology. J Cell Biochem 2007, 102:1375-1388.
19. Lastres P., Martin-Perez J., Langa C., Bernabeu C. Phosphorylation of the human-transforming-growth-factor-beta-binding protein endoglin. Biochem J 1994, 301(Pt. 3):765-768.
20. Koleva R.I., Conley B.A., Romero D., et al. Endoglin structure and function: determinants of endoglin phosphorylation by transforming growth factor-beta receptors. J Biol Chem 2006, 281:25110-25123.
21. Fernandez-Ruiz E., St-Jacques S., Bellon T., et al. Assignment of the human endoglin gene (END) to 9q34→qter. Cytogenet Cell Genet 1993, 64:204-207.
22. St-Jacques S., Cymerman U., Pece N., Letarte M. Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stromal cells. Endocrinology 1994, 134:2645-2657.
23. Bellon T., Corbi A., Lastres P., et al. Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 1993, 23:2340-2345.
24. Lastres P., Letamendia A., Zhang H., et al. Endoglin modulates cellular responses to TGF-beta 1. J Cell Biol 1996, 133:1109-1121.
25. Blanco F.J., Grande M.T., Langa C., et al. S-endoglin expression is induced in senescent endothelial cells and contributes to vascular pathology. Circ Res 2008, 103:1383-1392.
26. Santibanez J.F., Quintanilla M., Bernabeu C. TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2011, 121:233-251.
27. Guerrero-Esteo M., Sanchez-Elsner T., Letamendia A., Bernabeu C. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J Biol Chem 2002, 277:29197-29209.
28. Tian F., Zhou A.X., Smits A.M., et al. Endothelial cells are activated during hypoxia via endoglin/ALK-1/SMAD1/5 signaling in vivo and in vitro. Biochem Biophys Res Commun 2010, 392:283-288.
29. Santibanez J.F., Letamendia A., Perez-Barriocanal F., et al. Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling. J Cell Physiol 2007, 210:456-468.
30. Ten Dijke P., Goumans M.J., Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008, 11:79-89.
31. Conley B.A., Smith J.D., Guerrero-Esteo M., et al. Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis 2000, 153:323-335.
32. Sanchez-Elsner T., Botella L.M., Velasco B., et al. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002, 277:43799-43808.
33. Rius C., Smith J.D., Almendro N., et al. Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1. Blood 1998, 92:4677-4690.
34. Botella L.M., Sanchez-Elsner T., Sanz-Rodriguez F., et al. Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood 2002, 100:4001-4010.
35. Li C., Guo B., Ding S., et al. TNF alpha down-regulates CD105 expression in vascular endothelial cells: a comparative study with TGF beta 1. Anticancer Res 2003, 23:1189-1196.
36. Yoo J.K., Kim J., Choi S.J., et al. The hsa-miR-5739 modulates the endoglin network in endothelial cells derived from human embryonic stem cells. Biochem Biophys Res Commun 2011, 415:258-262.
37. Higashi Y., Noma K., Yoshizumi M., Kihara Y. Endothelial function and oxidative stress in cardiovascular diseases. Circ J 2009, 73:411-418.
38. Nachtigal P., Pospisilova N., Vecerova L., et al. Atorvastatin increases endoglin, SMAD2, phosphorylated SMAD2/3 and eNOS expression in ApoE/LDLR double knockout mice. J Atheroscler Thromb 2009, 16:265-274.
39. Nachtigal P., Vecerova L., Pospisilova N., et al. Endoglin co-expression with eNOS, SMAD2 and phosphorylated SMAD2/3 in normocholesterolemic and hypercholesterolemic mice: an immunohistochemical study. Histol Histopathol 2009, 24:1499-1506.
40. Trostdorf F., Buchkremer M., Harmjanz A., et al. Fibrous cap thickness and smooth muscle cell apoptosis in high-grade carotid artery stenosis. Eur J Vasc Endovasc Surg 2005, 29:528-535.
41. Bourdeau A., Dumont D.J., Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 1999, 104:1343-1351.
42. Ma X., Labinaz M., Goldstein J., et al. Endoglin is overexpressed after arterial injury and is required for transforming growth factor-beta-induced inhibition of smooth muscle cell migration. Arterioscler Thromb Vasc Biol 2000, 20:2546-2552.
43. Lastres P., Bellon T., Cabanas C., et al. Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol 1992, 22:393-397.
44. Piao M., Tokunaga O. Significant expression of endoglin (CD105), TGFbeta-1 and TGFbeta R-2 in the atherosclerotic aorta: an immunohistological study. J Atheroscler Thromb 2006, 13:82-89.
45. Li C., Mollahan P., Baguneid M.S., et al. A comparative study of neovascularisation in atherosclerotic plaques using CD31, CD105 and TGF beta 1. Pathobiology 2006, 73:192-197.
46. Luque A., Turu M., Juan-Babot O., et al. Overexpression of hypoxia/inflammatory markers in atherosclerotic carotid plaques. Front Biosci 2008, 13:6483-6490.
47. Luque A., Slevin M., Turu M.M., et al. CD105 positive neovessels are prevalent in early stage carotid lesions, and correlate with the grade in more advanced carotid and coronary plaques. J Angiogenes Res 2009, 1:6.
48. Post S., Peeters W., Busser E., et al. Balance between angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvessel density. J Vasc Res 2008, 45:244-250.
49. Slevin M., Turu M.M., Rovira N., et al. Identification of a 'snapshot' of co-expressed angiogenic markers in laser-dissected vessels from unstable carotid plaques with targeted arrays. J Vasc Res 2010, 47:323-335.
50. Bot P.T., Hoefer I.E., Sluijter J.P., et al. Increased expression of the transforming growth factor-beta signaling pathway, endoglin, and early growth response-1 in stable plaques. Stroke 2009, 40:439-447.
51. Strasky Z., Vecerova L., Rathouska J., et al. Cholesterol effects on endoglin and its downstream pathways in ApoE/LDLR double knockout mice. Circ J 2011, 75:1747-1755.
52. Nachtigal P., Pospisilova N., Jamborova G., et al. Endothelial expression of endoglin in normocholesterolemic and hypercholesterolemic C57BL/6J mice before and after atorvastatin treatment. Can J Physiol Pharmacol 2007, 85:767-773.
53. Vecerova L., Strasky Z., Rathouska J., et al. Activation of TGF-beta Receptors and Smad Proteins by Atorvastatin is Related to Reduced Atherogenesis in ApoE/LDLR Double Knockout Mice. J Atheroscler Thromb 2012, 19:115-126.
54. DiChiara M.R., Kiely J.M., Gimbrone M.A., et al. Inhibition of E-selectin gene expression by transforming growth factor beta in endothelial cells involves coactivator integration of Smad and nuclear factor kappaB-mediated signals. J Exp Med 2000, 192:695-704.
55. Nachtigal P., Pospisilova N., Jamborova G., et al. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice. Life Sci 2008, 82:708-717.
56. Koh K.K., Son J.W., Ahn J.Y., et al. Vascular effects of diet and statin in hypercholesterolemic patients. Int J Cardiol 2004, 95:185-191.
57. Zadelaar S., Kleemann R., Verschuren L., et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007, 27:1706-1721.
58. Rathouska J., Vecerova L., Strasky Z., et al. Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis. Pharmacol Res 2011, 64:53-59.
59. Jerkic M., Rivas-Elena J.V., Prieto M., et al. Endoglin regulates nitric oxide-dependent vasodilatation. Faseb J 2004, 18:609-611.
60. Jerkic M., Rodriguez-Barbero A., Prieto M., et al. Reduced angiogenic responses in adult Endoglin heterozygous mice. Cardiovasc Res 2006, 69:845-854.
61. Toporsian M., Gros R., Kabir M.G., et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 2005, 96:684-692.
62. Venkatesha S., Toporsian M., Lam C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006, 12:642-649.
63. Hawinkels L.J., Kuiper P., Wiercinska E., et al. Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res 2010, 70:4141-4150.
64. Kapur N.K., Heffernan K.S., Yunis A.A., et al. Usefulness of soluble endoglin as a noninvasive measure of left ventricular filling pressure in heart failure. Am J Cardiol 2010, 106:1770-1776.
65. Yanavitski M., Givertz M.M. Novel biomarkers in acute heart failure. Curr Heart Fail Rep 2011, 8:206-211.
66. Blann A.D., Wang J.M., Wilson P.B., Kumar S. Serum levels of the TGF-beta receptor are increased in atherosclerosis. Atherosclerosis 1996, 120:221-226.
67. Li C.G., Bethell H., Wilson P.B., et al. The significance of CD105, TGFbeta and CD105/TGFbeta complexes in coronary artery disease. Atherosclerosis 2000, 152:249-256.
68. Blaha M., Cermanova M., Blaha V., et al. Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia. Atherosclerosis 2008, 197:264-270.
69. Cruz-Gonzalez I., Pabon P., Rodriguez-Barbero A., et al. Identification of serum endoglin as a novel prognostic marker after acute myocardial infarction. J Cell Mol Med 2008, 12:955-961.
70. Cui S., Lu S.Z., Chen Y.D. Relationship among soluble CD105, hypersensitive C-reactive protein and coronary plaque morphology: an intravascular ultrasound study. Chin Med J (Engl) 2008, 121:128-132.
71. Ikemoto T., Hojo Y., Kondo H., et al. Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases. Heart Vessels 2011.
72. Endresen M.J., Morris J.M., Nobrega A.C., et al. Serum from preeclamptic women induces vascular cell adhesion molecule-1 expression on human endothelial cells in vitro: a possible role of increased circulating levels of free fatty acids. Am J Obstet Gynecol 1998, 179:665-670.
73. Wang Y., Adair C.D., Weeks J.W., et al. Increased neutrophil-endothelial adhesion induced by placental factors is mediated by platelet-activating factor in preeclampsia. J Soc Gynecol Invest 1999, 6:136-141.
74. Walshe T.E., Dole V.S., Maharaj A.S., et al. Inhibition of VEGF or TGF-{beta} signaling activates endothelium and increases leukocyte rolling. Arterioscler Thromb Vasc Biol 2009, 29:1185-1192.
75. Di Stefano R., Felice F., Balbarini A. Angiogenesis as risk factor for plaque vulnerability. Curr Pharm Des 2009, 15:1095-1106.
76. Bourdeau A., Faughnan M.E., Letarte M. Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia. Trends Cardiovasc Med 2000, 10:279-285.